In the study, ten subjects received placebo and ten received twice daily doses of QuadraMune for seven days.
Blood monocytes were extracted and treated with SARS-CoV-2 spike protein in vitro for three time points.
A significantly decreased production of the inflammatory cytokine interleukin-6 was reported at all three timepoints.
Last week Therapeutic Solutions International received a notice of allowance granting a patent on the immune modulatory and COVID-19 inhibiting properties of QuadraMune.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007